AI assistant
AstraZeneca PLC — Board/Management Information 2019
Oct 3, 2019
5229_dirs_2019-10-03_d2aa72a8-b389-454f-9d82-7965b3fafa60.html
Board/Management Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 7241O
AstraZeneca PLC
03 October 2019
3 October 2019 16:00 BST
Director Declaration
AstraZeneca PLC (the Company) today announced, pursuant to Listing Rule 9.6.14 R (2), that Pascal Soriot, Chief Executive Officer of the Company, is a director of Viela Bio, Inc. which recently completed an initial public offering and listed on the Nasdaq Global Market.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism (CVRM), and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
| Media Relations | ||
| Gonzalo Viña | +44 203 749 5916 | |
| Rob Skelding | Oncology | +44 203 749 5821 |
| Rebecca Einhorn | Oncology | +1 301 518 4122 |
| Matt Kent | BioPharmaceuticals | +44 203 749 5906 |
| Jennifer Hursit | Other | +44 203 749 5762 |
| Christina Malmberg Hägerstrand | Sweden | +46 8 552 53 106 |
| Michele Meixell | US | +1 302 885 2677 |
| Investor Relations | ||
| Thomas Kudsk Larsen | +44 203 749 5712 | |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Christer Gruvris | BioPharmaceuticals (CV, metabolism) | +44 203 749 5711 |
| Nick Stone | BioPharmaceuticals (respiratory, renal) | +44 203 749 5716 |
| Josie Afolabi | Other medicines | +44 203 749 5631 |
| Craig Marks | Finance, fixed income | +44 7881 615 764 |
| Jennifer Kretzmann | Corporate access, retail investors | +44 203 749 5824 |
| US toll-free | +1 866 381 72 77 |
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
RDNZXLFBKBFZFBQ